Tests and monitoring tools
Biomarker articles covering signals used to study, predict, monitor, or measure Crohn's disease and IBD activity or treatment response. Monitoring context emphasizes diagnosis, follow-up, disease activity, treatment response, and care decisions.
Page 4 of 4 · 190 articles
Risk-prediction tools like CDPATH™ could help people with Crohn’s disease and their doctors identify higher or lower short-term risk of complications and guide treatment conversations. This study tests how the tool...
If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.
Identifying patients at higher risk of hospitalization earlier could help clinicians target monitoring or treatment changes before clinical deterioration. Standard lab reference ranges may miss meaningful within-person...
FUT2 connects genetics, mucosal sugars, and the gut microbiome — pathways that could help explain why some people with IBD have different microbiomes or disease risk. If validated in trials, FUT2-targeted or...
This research links molecular subtypes of ulcerative colitis to infliximab (anti-TNF) response using an interpretable machine-learning method, which could help identify which patients are more or less likely to respond...
Oxidative stress may help explain some biological drivers of inflammation in Crohn’s disease and ulcerative colitis and could become a target for biomarkers or therapies in the future. Right now, the evidence is...
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
Fecal calprotectin is a noninvasive stool biomarker used to detect intestinal inflammation and to help distinguish IBD from noninflammatory conditions.
The study describes a new urine-based fluorescent biosensor that detected inflamed intestinal sites and tracked treatment response earlier and more sensitively than fecal calprotectin in a mouse model of IBD, which could...
PSC can progress to cirrhosis and cholangiocarcinoma; circulating multi-omic signatures that track severity and cancer-associated changes could help explain disease biology and lead to biomarkers for risk stratification...
Bowel urgency is a common symptom that may predict higher risk of treatment escalation, hospitalization, or surgery in UC even when bleeding and stool frequency look controlled. Better assessment of urgency in clinic...
Non-invasive urine biomarkers could make diagnosis and disease-activity monitoring easier and less invasive for people with IBD. Identifying metabolites linked to UC activity may help tailor monitoring without frequent...
If therapies that restore intestinal barrier function can be reliably tested and measured, future treatments might be developed that specifically target barrier healing — a mechanism linked to symptom relief and possibly...
Patients and clinicians choosing first‑line biologic therapy for ulcerative colitis may find evidence here that vedolizumab can provide sustained clinical benefit and a favorable safety profile in a biologic‑naïve...
The study uses single-cell RNA sequencing to pinpoint genes and regulatory networks that might help explain IBD biology and suggest new biomarkers or repurposed drugs. That information could guide future research toward...
New or improved fluorescent probes could enable more sensitive, noninvasive imaging of biochemical changes in the gut, which may aid research, earlier diagnosis, or monitoring of IBD and colorectal cancer.
IL-38 and a genetic variant (rs7599662) were linked to ulcerative colitis in this study, suggesting a possible new biomarker or therapeutic target. If validated, this could help researchers better understand UC...
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
The study identifies candidate metabolites that may underlie gut–brain biochemical crosstalk during colitis, which could point to early biomarkers or mechanistic targets relevant to IBD-related brain effects.
A coordinated national research network can accelerate studies that matter to people with IBD—like tracking real-world disease patterns, testing diet and psychosocial approaches, improving monitoring with biomarkers and...
People with Crohn’s disease facing surgery may have varying risks of complications; better biomarkers and models could help tailor perioperative care and decision-making. The review signals active research toward more...
People with long-standing ulcerative colitis face an increased risk of colorectal cancer; this study highlights PPARGC1A as a gene that may be downregulated early in that progression, which could eventually help identify...
A blood biomarker that rises with active ulcerative colitis could help patients and clinicians monitor disease activity without relying solely on invasive tests. This study reports that serum type 23 collagen ectodomain...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Researchers used genetics, microbiome, metabolism, and immune profiling together to nominate biological pathways and a four-gene signature that might help diagnose or explain ulcerative colitis. If validated later, these...
If validated, a blood biomarker (LRG) could help predict which people with Crohn’s disease are more likely to achieve remission and which biologic might be sustained over a year, informing treatment planning and...
People with UC have higher rates of low bone density, which raises fracture risk. This study links altered hormones (leptin, ghrelin, IGF‑1) and inflammation to lower BMD in UC, suggesting metabolic pathways that could...
New, non-invasive biomarkers and AI-driven multi-omic approaches could make diagnosis and treatment of IBD more precise, helping patients avoid invasive tests and improving chances of choosing effective therapies sooner.
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
If validated, a blood test for cytotoxic CD4+ T cells at diagnosis could help predict who is less likely to respond to anti‑TNF drugs, potentially allowing earlier selection of alternative therapies for some children...
The study identifies colonic gene-expression programs that correlate with treatment failure, higher surgery rates, and perianal disease in Crohn’s — findings that could guide future prognostic tests and targeted...
Distinguishing Crohn’s from ulcerative colitis can be hard and often requires invasive tests. A reliable blood test would speed diagnosis and help patients start the right treatments sooner. This study is an early step...
A biomarker that appears before inflammation could help detect Crohn’s disease earlier or predict relapses. Understanding early immune changes may point to new preventive strategies rather than only treating inflammation...
Cure8 found this source from precisionmedicineonline.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Biomarker. Open the original article for the full...
This study points to a possible microbiome biomarker (M. gnavus) tied to joint inflammation in people with Crohn’s disease, which could help explain why some patients develop arthritis and might eventually inform...
The study identifies a specific gut bacterium, Mediterraneibacter gnavus, that may act as a biomarker for joint inflammation in people with Crohn's disease. Understanding microbiome–immune links could eventually help...
If metabolomic blood markers can reliably indicate IBD risk years before symptoms, researchers may better understand disease development and eventually design earlier detection or prevention strategies. For patients, the...
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...
A noninvasive wearable that tracks inflammation markers could let people with IBD and their clinicians detect rising disease activity earlier and potentially act before symptoms develop. This may make monitoring less...
The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...
This paper highlights potential ubiquitination-related genes and immune-cell patterns that could help researchers understand Crohn’s disease biology and point to new targets for lab validation. For patients, it signals...
Researchers are trying to find blood biomarkers and a risk score that could predict who will develop Crohn’s disease before symptoms appear, which might enable earlier interventions or prevention in the future.
If successful, validated biomarkers and a blood risk score could allow clinicians to identify people at high risk of developing Crohn's disease and eventually test interventions to prevent symptoms. Prevention-focused...
This model aims to identify healthy first‑degree relatives at higher risk of developing Crohn’s disease before symptoms start, which could enable earlier monitoring or preventive strategies. The score uses simple...
